It would be interesting to investigate whether the mechanism of resistance to PRMT5-targeted therapies mediated by the oncogenic axis, MSI2/c-MYC/BCL-2, could be extrapolated to the other cancers. This evidence concerns the gene PRMT5 and cancer.